- Home
- DLHC vs ALXO Comparison
DLHC vs ALXO Comparison
Compare DLHC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- ALXO
- Stock Information
- Founded
- DLHC 1969
- ALXO 2015
- Country
- DLHC United States
- ALXO United States
- Employees
- DLHC N/A
- ALXO N/A
- Industry
- DLHC Business Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- ALXO Health Care
- Exchange
- DLHC Nasdaq
- ALXO Nasdaq
- Market Cap
- DLHC 80.6M
- ALXO 93.7M
- IPO Year
- DLHC N/A
- ALXO 2020
- Fundamental
- Price
- DLHC $5.59
- ALXO $1.59
- Analyst Decision
- DLHC
- ALXO Strong Buy
- Analyst Count
- DLHC 0
- ALXO 6
- Target Price
- DLHC N/A
- ALXO $3.30
- AVG Volume (30 Days)
- DLHC 10.7K
- ALXO 532.6K
- Earning Date
- DLHC 12-03-2025
- ALXO 11-10-2025
- Dividend Yield
- DLHC N/A
- ALXO N/A
- EPS Growth
- DLHC 80.25
- ALXO N/A
- EPS
- DLHC 0.31
- ALXO N/A
- Revenue
- DLHC $359,723,000.00
- ALXO N/A
- Revenue This Year
- DLHC N/A
- ALXO N/A
- Revenue Next Year
- DLHC N/A
- ALXO N/A
- P/E Ratio
- DLHC $18.54
- ALXO N/A
- Revenue Growth
- DLHC N/A
- ALXO N/A
- 52 Week Low
- DLHC $2.72
- ALXO $0.40
- 52 Week High
- DLHC $9.58
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- DLHC 58.98
- ALXO 47.86
- Support Level
- DLHC $5.53
- ALXO $1.53
- Resistance Level
- DLHC $5.88
- ALXO $1.90
- Average True Range (ATR)
- DLHC 0.16
- ALXO 0.16
- MACD
- DLHC 0.03
- ALXO -0.05
- Stochastic Oscillator
- DLHC 70.21
- ALXO 13.61
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.